14.03
Schlusskurs vom Vortag:
$13.94
Offen:
$14
24-Stunden-Volumen:
260.15K
Relative Volume:
0.15
Marktkapitalisierung:
$888.02M
Einnahmen:
$15.84M
Nettoeinkommen (Verlust:
$-308.48M
KGV:
-2.1651
EPS:
-6.48
Netto-Cashflow:
$-153.08M
1W Leistung:
-0.98%
1M Leistung:
-2.70%
6M Leistung:
-20.27%
1J Leistung:
+216.76%
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Vergleichen Sie QURE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
QURE
Uniqure N V
|
14.04 | 888.02M | 15.84M | -308.48M | -153.08M | -6.48 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
451.60 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
536.80 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
323.48 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
554.00 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.50 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
2024-10-10 | Fortgesetzt | Raymond James | Outperform |
2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
2022-03-17 | Hochstufung | UBS | Neutral → Buy |
2021-06-15 | Eingeleitet | BTIG Research | Buy |
2021-05-21 | Eingeleitet | UBS | Neutral |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
2020-11-11 | Eingeleitet | Berenberg | Buy |
2020-11-09 | Eingeleitet | Jefferies | Buy |
2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2019-12-03 | Eingeleitet | Cowen | Outperform |
2019-12-03 | Eingeleitet | Goldman | Buy |
2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
2019-10-11 | Eingeleitet | Stifel | Buy |
2019-09-25 | Eingeleitet | Bernstein | Outperform |
2019-09-12 | Eingeleitet | Mizuho | Buy |
2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
uniQure: Price And Value Have Caught Up (NASDAQ:QURE) - Seeking Alpha
uniQure shareholders approve executive compensation, board reappointments By Investing.com - Investing.com South Africa
uniQure shareholders approve executive compensation, board reappointments - Investing.com
uniQure (QURE) Appoints Kylie O'Keefe to Advance Global Strategy - GuruFocus
uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer By Investing.com - Investing.com South Africa
uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer - Investing.com India
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer - GlobeNewswire
uniQure Prepares for Historic Huntington's Disease Treatment Launch with Key Executive Hire - Stock Titan
uniQure (NASDAQ:QURE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Learn to Evaluate (QURE) using the Charts - news.stocktradersdaily.com
uniQure (QURE) Positioned for Growth Amid Regulatory Changes - GuruFocus
RFK Jr. looks to fast track rare disease drug approvals (updated) - Seeking Alpha
Bank of America Corp DE Has $1.22 Million Stock Holdings in uniQure (NASDAQ:QURE) - Defense World
Stock Traders Buy Large Volume of uniQure Call Options (NASDAQ:QURE) - Defense World
stifel reiterates buy rating on uniQure stock after CEO meeting By Investing.com - Investing.com UK
uniQure (NASDAQ:QURE) Short Interest Update - Defense World
H.C. Wainwright reaffirms Buy rating on uniQure stock after FDA meeting By Investing.com - Investing.com South Africa
H.C. Wainwright reaffirms Buy rating on uniQure stock after FDA meeting - Investing.com Australia
Chardan Capital Reaffirms Buy Rating for uniQure (NASDAQ:QURE) - MarketBeat
uniQure aligns with FDA on Huntington’s therapy path By Investing.com - Investing.com South Africa
uniQure provides regulatory update on AMT-130 for Huntington’s Disease - TipRanks
UniQure Reaches Alignment With FDA on Potential Huntington's Disease Gene Therapy - marketscreener.com
Transcript : UniQure N.V.Special Call - marketscreener.com
UniQure Provides Regulatory Update On Amt-130 For Huntington'S Disease - marketscreener.com
uniQure (QURE) Advances Gene Therapy for Huntington's Disease wi - GuruFocus
uniQure aligns with FDA on Huntington’s therapy path - Investing.com
uniQure (QURE) Advances Gene Therapy for Huntington's Disease with FDA Alignment | QURE Stock News - GuruFocus
uniQure Advances AMT-130 for Huntington's Disease with FDA Alignment, BLA Submission Planned for Q1 2026 - Nasdaq
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - GlobeNewswire
FDA Green Lights Accelerated Approval Plan for First-Ever Huntington's Disease Gene Therapy Treatment - Stock Titan
uniQure (NASDAQ:QURE) Given “Buy” Rating at Chardan Capital - Defense World
HC Wainwright maintains Buy rating on uniQure stock, $70 target By Investing.com - Investing.com UK
uniQure (NASDAQ:QURE) Receives Buy Rating from HC Wainwright - Defense World
QURE: HC Wainwright & Co. Reiterates Buy Rating for uniQure | QU - GuruFocus
uniQure presents case study of first patient dosed with AMT-260 - TipRanks
uniQure (QURE) Gains Support Following Positive Data from Epilep - GuruFocus
uniQure (QURE) Unveils Key Data from Gene Therapy Trial | QURE S - GuruFocus
uniQure early AMT-260 data encouraging, says H.C. Wainwright - TipRanks
uniQure (QURE) Unveils Key Data from Gene Therapy Trial | QURE Stock News - GuruFocus
uniQure Presents Clinical Case Study of First Patient Dosed - GlobeNewswire
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) | QURE Stock News - GuruFocus
Revolutionary Gene Therapy Cuts Epilepsy Seizures by 92% in First Patient DataUniQure's Breakthrough - Stock Titan
Down 40% in 2025, Should You Buy the Dip in Marvell Stock? - The Globe and Mail
Long Term Trading Analysis for (QURE) - news.stocktradersdaily.com
uniQure's AMT-130 Gene Therapy Warrants An Upgrade (NASDAQ:QURE) - Seeking Alpha
Northern Trust Corp Buys 1,923 Shares of uniQure (NASDAQ:QURE) - Defense World
Millennium Management LLC Cuts Position in uniQure (NASDAQ:QURE) - Defense World
uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen - Defense World
uniQure N.V. (QURE) Stock Analysis: Exploring a 133.81% Potential Upside in Biotechnology - DirectorsTalk Interviews
Fed. Circ. Backs Pfizer Win Against Gene Therapy Patents - Law360
Stock Traders Purchase High Volume of Put Options on uniQure (NASDAQ:QURE) - Defense World
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Uniqure N V-Aktie (QURE) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
POST LEONARD E | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
29,937 |
Kaye Jack | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
20,439 |
Jacques Rachelle Suzanne | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
28,346 |
Gut Robert | Director |
Jun 20 '25 |
Sale |
14.45 |
3,336 |
48,205 |
56,879 |
Balachandran Madhavan | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,697 |
Meek David D. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
34,190 |
Potts Jeannette | Chief Legal Officer |
Jun 16 '25 |
Sale |
15.14 |
4,670 |
70,704 |
115,073 |
Kapusta Matthew C | CEO, Managing Director |
Mar 04 '25 |
Sale |
10.29 |
28,341 |
291,629 |
651,454 |
Abi-Saab Walid | Chief Medical Officer |
Mar 04 '25 |
Sale |
10.29 |
1,350 |
13,891 |
151,903 |
KLEMT CHRISTIAN | Chief Financial Officer |
Mar 04 '25 |
Sale |
10.29 |
10,438 |
107,407 |
217,730 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):